ArticleFrontiers in pharmacology2026
Skeletal effects of JAK1/2 inhibition versu
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Janus kinase inhibitors (JAKi) are increasingly used in rheumatoid arthritis (RA), yet comparative data on systemic effects beyond joint inflammation remain limited. Because chronic inflammation promotes generalized bone loss and IL-6-driven osteoclastogenesis, we compared the skeletal effects of baricitinib and tocilizumab over 12 months. Methods: We performed an exploratory Results: No significant differences in BMD changes were observed between groups. Mean spine BMD increased by +8.2 mg/cm Conclusion: JAK1/2 inhibition with baricitinib and IL-6 receptor blockade with tocilizumab showed comparable 12-month effects on lumbar spine and femoral neck BMD. These findings suggest that preservation of bone health in RA is more closely linked to effective suppression of inflammatory activity than to a detectable advantage of one targeted mechanism over the other.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.